This database contains 175 studies, archived under the term: "administration & dosage"
Click here to filter this large number of results.
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
Black, Ronald S.,
Sperling, Reisa A.,
Safirstein, Beth,
Motter, Ruth N.,
Pallay, Allan,
Nichols, Alice,
Grundman, Michael
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5 mg/kg or placebo (6 active, 2 placebo for 0.5 […]
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial
Snitz, Beth E.,
O'Meara, Ellen S.,
Carlson, Michelle C.,
Arnold, Alice M.,
Ives, Diane G.,
Rapp, Stephen R.,
Saxton, Judith,
Lopez, Oscar L.,
Dunn, Leslie O.,
Sink, Kaycee M.,
DeKosky, Steven T.
Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]
Long-term effects of rivastigmine capsules in patients with traumatic brain injury
Silver, Jonathan M.,
Koumaras, Barbara,
Meng, Xiangyi,
Potkin, Steven G.,
Reyes, Patricio F.,
Harvey, Philip D.,
Katz, Douglas I.,
Gunay, Ibrahim,
Arciniegas, David B.
Objective: To investigate the safety, tolerability and efficacy of rivastigmine capsules (3-12 mg/day) in a 26-week, multi-centre, open-label extension of a double-blind study.; Methods: Patients with traumatic brain injury (TBI) and persistent cognitive impairment who had received rivastigmine (3-6 mg/day) or placebo for 12 weeks could enter the extension study and receive rivastigmine (< or […]
Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia
Schmidt, Reinhold,
Alf, Claude,
Bancher, Christian,
Benke, Thomas,
Berek, Klaus,
Dal-Bianco, Peter,
Führwürth, Gerhard,
Imarhiagbe, Douglas,
Jagsch, Christian,
Lechner, Anita,
Rainer, Michael,
Reisecker, Franz,
Rotaru, Juliana,
Uranüs, Margarete,
Walter, Andreas,
Winkler, Andreas,
Wuschitz, Albert
We performed a 6-month open-label study on the use of the transdermal rivastigmine patch in clinical routine in 103 patients with Alzheimer’s disease from 25 outpatient services in Austria. After baseline, safety and tolerability of the 10 cm2–rivastigmine patch was assessed at week 4, 12 and 24 in all patients. A Mini Mental State Examination […]
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Gilman, S.,
Fox, N. C.,
Blennow, K.,
Raskind, M.,
Sabbagh, M.,
Honig, L. S.,
Doody, R.,
van Dyck, C. H.,
Mulnard, R.,
Barakos, J.,
Gregg, K. M.,
Liu, E.,
Lieberburg, I.,
Schenk, D.,
Black, R.,
Grundman, M.
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]
The effects of glucose ingestion and glucose regulation on memory performance in older adults with mild cognitive impairment
Riby, L. M.,
Marriott, A.,
Bullock, R.,
Hancock, J.,
Smallwood, J.,
McLaughlin, J.
Background/objectives: Previous research investigating the impact of glucose ingestion and/or improvements in glucose regulation has found selective cognitive facilitation on episodic memory tasks in successful ageing and dementia. The present study aimed to extend this research to mild cognitive impairment (MCI).; Subjects/methods: In a repeated-measures design, 24 older adults with and 24 older adults without […]